Salubris(SZ:002294) Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2025-12-20 06:22Core Viewpoint - Shenzhen Sinopharm Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for clinical trials of its innovative small molecule drug SAL0137, aimed at treating elevated lipoprotein(a) levels, which are independent risk factors for cardiovascular diseases [1][2]. Group 1: Clinical Trial Approval - The company has been granted a Clinical Trial Approval Notice for SAL0137, allowing it to conduct clinical trials for treating elevated lipoprotein(a) levels [1]. - Elevated lipoprotein(a) is linked to various cardiovascular diseases, including coronary heart disease and ischemic stroke, increasing the risk through multiple mechanisms [1]. Group 2: Potential Impact and Development - If SAL0137 is successfully developed and approved, it could provide new treatment options for patients and address unmet clinical needs, enhancing the company's product pipeline in chronic disease management [2]. - The company will conduct clinical trials in accordance with national drug registration regulations, and the timeline from clinical trials to market approval is subject to various uncertainties, which may not have an immediate impact on the company's performance [2].